FL-AMGTA
23.2.2021 14:01:10 CET | Business Wire | Press release
The Additive Manufacturer Green Trade Association (AMGTA), a global trade organization created to promote the environmental benefits of additive manufacturing (AM), announced today that eight additional leading AM organizations have joined the trade group to advance sustainability in AM, bringing its membership ranks to twenty members.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210223005155/en/
Joining the AMGTA as new Participating Members are: BASF 3D Printing Solutions , a provider of 3D printing solutions along the entire additive manufacturing value chain under the brand Forward AM; DyeMansion , the global leader in automated post-processing workflows for industrial polymer 3D-printing; Fraunhofer Institute for Laser Technology (ILT) , one of the world’s leading research institutes in the field of laser-based additive manufacturing; HP, Inc. , a global leader of 3D printing and digital manufacturing solutions for sustainable production; Rusal America , a subsidiary of Rusal, the world’s leading producer of low-carbon aluminum; TRUMPF , one of the world’s leading companies for machine tools, laser technology, and additive manufacturing for industrial applications; and 6K , a leading metal powder producer that is setting a new AM “green” standard by leveraging sustainable sources as feedstock for premium powder production with its UniMelt® platform.
These new Participating Members will serve alongside existing Participating Members AMEXCI AB , a resource for futureproofing Nordic Industries, accelerating the adoption of additive manufacturing technologies; Danish AM Hub , Denmark’s focal point for the additive manufacturing ecosystem; EOS , the world’s leading technology supplier in the industrial 3D printing of metals and polymers; GE Additive , a world leader in additive design and manufacturing, a pioneering process that has the power and potential to transform businesses; Materialise , the backbone of 3D printing, incorporating three decades of experience into pioneering software solutions and services; National Manufacturing Institute Scotland , a group of industry-led manufacturing R&D facilities transforming skills, productivity, and innovation in Scotland; Siemens Digital Industries Software , a driver of design, engineering and manufacturing transformation with its Xcelerator digital enterprise portfolio; SLM Solutions Inc. , the leading provider of industrial metal 3D printing machines focused on metal additive manufacturing and multi-laser technology; and Stryker , one of the world’s leading medical technology companies.
“I’m excited to officially welcome ExOne aboard as a new Founding Member company of the AMGTA, as well as each of our new Participating Member organizations,” said Sherry Handel, Executive Director of the AMGTA. “Their dedication to support our trade group’s mission well-positions the AMGTA for continued growth and helps to fund new sustainability research projects in additive manufacturing. I am looking forward to working with all of our members as we expand the AMGTA as a key industry resource in advancing sustainability in the AM industry this year and beyond.”
About AMGTA
The AMGTA was launched in November 2019 to promote the environmental benefits of additive manufacturing (AM) over traditional methods of manufacturing. The AMGTA is a non-commercial, unaffiliated organization open to any additive manufacturer or industry stakeholder that meets certain criteria relating to sustainability of production or process.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210223005155/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom